FDA Approves First Precision-Engineered Allogeneic Cell Therapy Designed to Reduce GvHD

Allogeneic stem cell transplant is a potentially curative option for patients with certain blood cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS). However, these transplants come with significant risks. One of the biggest concerns is graft-versus-host disease (GvHD), which occurs when donor-derived immune cells attack the recipient’s tissues, often leading to serious complications. 

Conventional approaches to GvHD prevention have largely relied on pharmacologic immunosuppression, including calcineurin inhibitors, methotrexate, and post-transplant cyclophosphamide. While these strategies have reduced the incidence and severity of GVHD, they are associated with important tradeoffs, including delayed immune reconstitution, increased susceptibility to infections, impaired graft-versus-leukemia activity, organ toxicities, and prolonged dependence on immunosuppressive medications.<

More recently, graft engineering has emerged as an innovative strategy that seeks to reduce GVHD by optimizing the cellular composition of the donor graft itself, rather than relying solely on post-transplant pharmacologic immunosuppression.

Now, a novel investigational therapy offers new hope. Orca-T, developed by Orca Bio, is shifting this risk-benefit balance in favor of better outcomes.

Orca-T: A Targeted Approach to T-Cell Transplant

Orca-T is a precision-engineered cellular therapy that combines highly purified donor-derived polyclonal regulatory T cells, hematopoietic stem cells, and conventional T cells. It is intended to be a safer transplant alternative for patients with blood cancers, preserving the graft-versus-leukemia effect while minimizing the risk of GvHD.

A Step Closer to Transforming Cancer Care

Moffitt Cancer Center served as a clinical trial site for the Phase III study and is well-positioned to offer the therapy once it receives regulatory approval. With one of the largest and most active Blood and Marrow Transplant and Cellular Immunotherapy (BMT CI) programs in the Southeast, Moffitt continues to lead the charge in developing new and effective immunotherapies. Through initiatives such as our partnerships for Cell Therapy & Gene Engineering, Moffitt helps secure various FDA designations for breakthrough treatments to prevent and cure cancer.

 The U.S. Food and Drug Administration approved Orca-T on June 30, marking the first FDA-approved precision-engineered allogeneic cell therapy designed to optimize donor graft composition, with the goal of reducing GVHD while maintaining favorable transplant outcomes.

Approximately 46,000 people are diagnosed with AML, ALL, and MDS in the U.S. each year, but only a fraction of them receive an allogeneic stem cell transplant within the current paradigm. For eligible patients, transplant remains an important potentially curative option. Approaches such as Orca-T that reduce transplant related complications while preserving efficacy have the potential to expand access and improve long-term outcomes for our patients.

-Rawan Faramand, M.D., Associate Member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center.

By supporting research and providing access to advanced therapies, Moffitt is helping to ensure that promising treatments like Orca-T are available to patients across Florida and beyond.

To refer a patient to Moffitt, complete our online form or contact a physician liaison for assistance. As part of our efforts to shorten referral times as much as possible, online referrals are normally responded to within 24 - 48 hours.